Posted on

anadrol steroids

6960

Overdosing Symptoms: dizziness, restlessness, disturbance of consciousness, blood pressure, tachycardia, bradycardia. Treatment: at the first signs of overdose during the injection, you must stop the introduction of the drug, to give the patient a horizontal position anadrol steroids to provide a free airway, monitor your heart rate and blood pressure. In case of violation of breath – oxygen, endotracheal intubation, mechanical ventilation of lungs (central analeptics contraindicated); in convulsions – slow intravenous short-acting barbiturates while supplying oxygen and hemodynamic control; in severe circulatory disorders and shock – intravenous infusion of electrolyte solutions and plasma substitutes, corticosteroids, albumin; in vascular collapse and increasing bradycardia – slow intravenous epinephrine 0.1 mg, followed by intravenous drip under the control of heart rate and blood pressure; in severe tachycardia and tachyarrhythmia – intravenous beta-blockers (selective); when the blood pressure increase – peripheral vasodilators. Oxygen therapy and monitoring indicators of circulatory necessary in all cases.

Interaction with other drugs
Hypertensive effect sympathomimetic epinephrine such as amines can be enhanced by tricyclic antidepressants and monoamine oxidase inhibitors.
The interaction of this type is described for epinephrine and norepinephrine when they are used as a vasoconstrictor in concentrations of 1: 25000 and 1:. 80,000, respectively,
should not be prescribed the drug to treatment with non-selective beta-blockers, as in this case, high risk of hypertensive crisis and severe anadrol steroids bradycardia.
Valium action artikaina reinforce and extend vasoconstrictor drugs.

Cautions
Ubistezin contains sulfites, which may enhance the anaphylactic reaction.
The drug should not be administered intravenously. They should not be injected into the area of inflammation.
Eating is possible only after the restoration of sensitivity.
In order to prevent infection (including hepatitis) is necessary whenever domestic solution from vials or ampoules always use new, sterile syringes and needles. Opened cartridges can not be used again for other patients (risk of hepatitis C).
Do not use a damaged cartridge.
Do not cause any harmful effects on the fetus (except possible bradycardia) in any technology application and dosage.

Effects on ability to drive vehicles and management mechanisms .
In special tests did not reveal clearly the effect of the drug on the concentration of attention and speed of motor responses. However, due to the fact that the patient’s preoperative anxiety and stress due to surgery, can have an impact on the effectiveness of, the anadrol steroids dentist must be individually, in each case, decide on the admission of the patient to the management of transport or operating machinery.

Anadroxyl and Sustaxyl

Posted on

oxymethobol

6961

Articaine with submucosal administration in the mouth has a high diffusion capacity. Contact proteins is 95%. The active substance in minimally cross the placental barrier, virtually excreted in breast milk, half-life is 25 minutes.

Indications
Infiltration and conduction anesthesia oxymethobol in dentistry (especially in patients with severe concomitant somatic diseases), including during the following manipulations:

 

  • uncomplicated removal of one or more teeth;
  • filling cavities, turning of the teeth before dissection.Contraindications
  • Hypersensitivity to articaine, epinephrine, sulfites, and any ancillary components of the formulation;
  • paroxysmal tachycardia and other tachyarrhythmias;
  • bronchial asthma with hypersensitivity to sulfites;
  • angle-closure glaucoma, simultaneous reception of non-selective beta-blockers;
  • a severe form of liver failure (porphyria);
  • hyperthyroidism;
  • concomitant therapy monoamine oxidase inhibitors or tricyclic antidepressants,
  • cardiogenic shock.With caution used in the following cases:
  • chronic heart failure,
  • intraventricular and atrioventricular heart block,
  • inflammation in the intended anesthetic
  • cholinesterase deficiency,
  • renal failure,
  • diabetes,
  • arterial oxymethobol hypertension,
  • childhood,
  • elderly age,
  • severe general condition, debilitated patients.Use during pregnancy and lactation
    is possible to use the drug during pregnancy. If necessary, use in nursing mothers is not necessary to interrupt the feeding, since the active substances are not excreted in breast milk in clinically relevant amounts.Dosing and Administration
    In uncomplicated removal of the upper jaw teeth in the absence of inflammation is usually injected into the submucosa in the transition folds from the vestibular side of 1.7 ml of the drug (for each tooth). In some cases, it may require additional administration from 1 to 1.7 ml of the drug to achieve full anesthesia. In most cases there is no need to perform painful palatal injections oxymetholone. For anesthesia of palatal sections and suturing to create a palatine depot needs about 0.1 ml per injection. When you delete several adjacent teeth number of injections can usually be limited. In the case of the removal of the premolars of the mandible in the absence of inflammation can be dispensed with mandibular anesthesia, because infiltration anesthesia provided by injection of 1.7 ml per tooth is usually sufficient. If this path is not able to achieve the desired effect, it is necessary to perform an additional injection of 1-1.7 ml of the drug in the submucosa in the transitional fold of the lower jaw from the oxymethobol vestibular side. If in this case did not reach full anesthesia is necessary to blockade the mandibular nerve.
    To prepare the tooth cavity or to the sealing treatment under any tooth crown, with the exception of the lower molars, shows the introduction of the drug in doses of from 0.5 to 1.7 ml each tooth on the type of infiltration anesthesia from vestibular side. The exact amount depends on the desired depth and duration of the procedure. When performing a medical procedure may be administered to an adult 7 articaine mg per 1 kg of body weight. Duration of anesthesia, within which to conduct intervention is 30-45 minutes.Side effects:
    The drug is usually well tolerated, but may develop the following side effects: On the part of the central nervous system (depends on the applied dose): headache, impaired consciousness until his loss, respiratory disorders, up until it stops, muscle tremors, involuntary twitching muscles, sometimes progressing up to generalized seizures, the part of the digestive system: nausea, vomiting, diarrhea; the part of the organ of vision: rarely – “blurred” in the eyes, transient blindness. cardio-vascular system: moderately expressed disturbances of hemodynamics, manifested in lowering blood pressure, tachycardia or bradycardia, inhibition of cardiovascular activity that extreme, can lead to collapse and cardiac arrest, which threatens the patient’s life. Allergic reaction: swelling or inflammation at the injection site; in other areas – skin redness, itching, conjunctivitis, rhinitis, angioedema varying severity (including swelling of the upper and / or lower lips and / or cheeks, glottis with difficulty swallowing, hives, difficulty breathing).All these phenomena may progress to anaphylactic shock. Local reactions: swelling or inflammation at the injection site; occurrence of ischemic zones in the injection site (up to the development of tissue necrosis – Accidental intravascular administration); Other: often observed headaches related probably to the presence of the drug epinephrine; other side effects due to the action of epinephrine oxymethobol (tachycardia, arrhythmia, increased blood pressure) occur rarely; nerve damage (up to the development of paralysis) – occurs only in violation of the injection technique.

http://roids-uk.co/for-sale/oxymetholone/

Posted on

anadrol for women

6963

As with other H reductase inhibitors (statins), when therapy with  moderate possible (more than 3 times the upper limit of normal increased serum activity of “liver” transaminases:  Prior to initiation of therapy, after 6 weeks and 12 weeks after starting or after increasing the dose, liver function tests need to be monitored  . Liver function should be monitored and the appearance of clinical signs of liver damage. In the case of increasing the activity of anadrol for women, their activity anadrol for women should be monitored as long as it is not normal.  Should be used with caution in patients who abuse alcohol and / or have a history of liver disease (see. Section “Precautions”). Liver disease in the active stage or increased activity of “liver” transaminases blood plasma of unknown origin is a contraindication for use (sm. section “Contraindications”). Prevention of stroke by means of intensive lipid-lowering therapy. in a retrospective analysis of the various subtypes of stroke in people who do not have coronary heart disease , who recently had a stroke or transient ischemic attack, it was detected at higher risk of hemorrhagic stroke patients receiving atorvastatin 80 mg compared with placebo. Particularly high risk observed in patients after a hemorrhagic stroke or lacunar infarct at study entry. For patients who have had a hemorrhagic stroke or lacunar infarction and receiving atorvastatin 80 mg, risk / benefit ratio is ambiguous, and should carefully assess the potential risk of hemorrhagic stroke before treatment may be assumed in patients with diffuse myalgia, muscle tenderness or weakness and / or marked increase in activity . Treatment should be discontinued in the event expressed increasing  or in the presence of confirmed or suspected myopathy. When using other inhibitors of HMG-Co reductase inhibitors (statins) may increase the risk of myopathy with the concomitant use of cyclosporine, fibrates, erythromycin, nicotinic acid lipid-lowering doses (more than 1 g / d) or azole antifungals. Applying medication anadrol for women in combination with fibrates, erythromycin, immunosuppressants, azole antifungals or niacin in lipid-lowering doses (more than 1 g / day), you need to weigh the potential benefits and risks of treatment  . Very rarely reported cases of immune-mediated necrotising myopathy during or after the treatment with statins, including atorvastatin.

Immune-mediated necrotizing myopathy is clinically characterized by muscle weakness in the upper extremities and the increased concentration of plasma, persisting despite the discontinuation of statin treatment. If necessary, combination therapy should consider the use of these drugs at lower initial and maintenance doses. It is recommended periodic monitoring of the activity . The combined use of atorvastatin and fusidic acid is not recommended, therefore, to consider the suspension of atorvastatin during the use of fusidic acid. Patients should be warned that you must immediately consult a doctor if unexplained aches or muscle weakness, particularly if accompanied by malaise or fever! In applying the anadrol for women other inhibitors of  reductase inhibitors (statins) are described rare cases of rhabdomyolysis with acute renal failure due to myoglobinuria. If you have symptoms of possible myopathy or presence of renal failure factor risk against the background of rhabdomyolysis (eg, severe acute infection, hypotension, major surgery, trauma, metabolic and endocrine disorders, and uncontrolled seizures) therapy  should suspend or cancel. interstitial lung disease has been reported on the extremely rare cases of interstitial lung disease with the use of some statins, especially with prolonged therapy.

Clinical manifestations include dyspnea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected to develop interstitial lung disease, statin therapy should be discontinued. Diabetes Some studies suggest that the use of statins, as a class, can lead to increased blood glucose levels, and in some patients with an increased risk of developing diabetes in the future It can cause the level of hyperglycemia in which the required standard antidiabetic therapy. However, such a risk is negligible in comparison with a reduction in cardiovascular risk statins and therefore should not cause withdrawal of treatment with anadrol for women statins. Patients at riskshould be under control, as the clinical and biochemical, in according to national standards of care.

Posted on

oxymethalone

6964

The risk of myopathy during treatment with oxymethalone reductase inhibitors is increased by simultaneous use of cyclosporine, erythromycin, clarithromycin, immunosuppressive, anti-fungal drugs (azole derivatives) due to a possible increase in the serum concentrations of atorvastatin.
While the use of HIV protease inhibitors – indinavir, ritonavir – an increased risk of myopathy.
a similar interaction is possible with the concomitant use of atorvastatin with fibrates and nicotinic acid in the lipid-lowering doses (more than 1 g / day). since atorvastatin is metabolized  isoenzyme, the combined use with inhibitors of this isoenzyme may increase atorvastatin plasma concentration. The degree of interaction and the effect of increasing concentrations of atorvastatin are determined by the variability  isoenzyme impact on. Transport protein inhibitors Atorvastatin and its metabolites are substrates of the transport protein  inhibitors (eg, cyclosporine) may increase the bioavailability of atorvastatin. Thus, the use of atorvastatin and 10 mg of cyclosporin dose of 5.2 mg / kg / day results in an increase in the plasma concentration of atorvastatin in 7.7 times. Erythromycin / clarithromycin With simultaneous use of atorvastatin and 10 mg of erythromycin (500 mg of 4 twice daily) or clarithromycin (500 mg, 2 times a day), which inhibit the isoenzyme cytochrome  is observed increase atorvastatin plasma concentration (40% – when used with erythromycin and 56% – when used with clarithromycin). inhibitors protease Concomitant use of atorvastatin with inhibitors of proteases, known as inhibitors of the isoenzyme cytochrome accompanied by an increase atorvastatin plasma concentration (while the use of of atorvastatin increased by 40%). Diltiazem Combined use of atorvastatin 40 mg with diltiazem in doses 240 mg increases the concentration of atorvastatin in plasma.Cimetidine clinically significant interaction atorvastatin cimetidine have been identified. itraconazole Concomitant use of atorvastatin in doses ranging from 20 mg to 40 mg itraconazole, 200 mg conducts to 3 hkratnomu increase value  atorvastatin. Grapefruit juice since grapefruit juice contains one or more components which inhibit the isozyme, its excessive use (more than 1.2 liters per day for 5 days) may cause an increase in the concentration of atorvastatin in plasma. Inductors isoenzyme  Combined use with atorvastatin isoenzyme inducers (e.g., efavirenz or rifampicin) may reduce the concentration of atorvastatin in plasma. Due to the dual interaction mechanism with rifampicin (inducer of oxymethaloneand an inhibitor of the transport protein hepatocyte  is not recommended the simultaneous use of atorvastatin and rifampicin as deferred atorvastatin after administration of rifampicin results in a significant reduction in atorvastatin plasma concentrations. Antacids In an application inside of atorvastatin and suspension containing magnesium and aluminum hydroxides, atorvastatin plasma concentration is reduced by about 35%, but the degree of reduction in LDL cholesterol concentration is not changed. phenazone atorvastatin not affect the pharmacokinetics of phenazone, so interaction with other drugs metabolized by the same isozyme not expected. colestipolLipid-lowering effect of combination with colestipol than that for each drug individually, despite the decrease in the concentration of atorvastatin by 25% at its simultaneous application with colestipol. fusidic acid interaction studies of atorvastatin and fusidic acid have not been conducted. As is the case with other statins, post-marketing study joint application of atorvastatin and fusidic acid reported side effects on muscles, including rhabdomyolysis. The mechanism of interaction is unknown. These patients require close monitoring and may temporarily cancel receiving atorvastatin. Colchicine Although interaction studies of atorvastatin and colchicine have not been conducted, reported cases of myopathy when combined with colchicine, and while the appointment of atorvastatin and colchicine should use caution.Digoxin Repeated use of digoxin and atorvastatin 10 mg of the equilibrium concentration of digoxin in plasma did not change. However, the application of digoxin in combination with atorvastatin 80 mg / day.digoxin plasma concentration increases by approximately 20%. Patients taking digoxin in combination with atorvastatin, require monitoring of digoxin plasma concentrations. Azithromycin With the simultaneous use of atorvastatin at a dose of 10 mg 1 time / day and azithromycin 500 mg 1 times / day of atorvastatin plasma concentration does not change. Oral contraceptives with simultaneous use of atorvastatin and oral contraceptive containing norethisterone and ethinyl estradiol, there is a significant increase in AUC of norethisterone and ethinyl estradiol by approximately 30% and 20%, respectively, which should be considered when selecting an oral contraceptive. terfenadine atorvastatin while the use of terfenadine has no clinically significant effect on the pharmacokinetics of oxymethalone terfenadine. warfarin in patients who are taking warfarin for a long time, atorvastatin 80 mg per day several shortens prothrombin time during the first days of joint application. This effect disappears after 15 days, the simultaneous application of these drugs. Although cases of clinically significant changes in the anticoagulant effect was reported very rarely, you should determine the prothrombin time in patients taking coumarin anticoagulants, before and quite often at the beginning of treatment with atorvastatin, to ensure that no significant changes in prothrombin time. Once registered stable prothrombin time, it can be inspected at intervals for normal patients taking coumarin anticoagulants. If you change the dose or discontinuing treatment, these measures should be repeated. There was no connection between the use of atorvastatin and bleeding or change in prothrombin time in patients not taking anticoagulants. Amlodipine With simultaneous use of atorvastatin 80 mg and amlodipine 10 mg the pharmacokinetics of atorvastatin at steady state is not changed. Other lipid-lowering drugs With simultaneous use of atorvastatin other lipid-lowering drugs (for example, ezetimibe, gemfibrozil, fibric acid derivative) in the lipid-lowering doses increases the risk of developing rhabdomyolysis. other concomitant therapy When combined with atorvastatin antihypertensive agents and estrogen (as a replacement therapy) – clinically significant interactions have been identified.

 

special instructions

Posted on

anodrol

6966

According to the anodrol, undesirable effects are classified according to their rate of development as follows: common , including isolated reports; the frequency is unknown anodrol – according to available data to set the frequency of occurrence is not possible. On the part of the immune system often: allergic reaction; very rare: anaphylaxis. On the part of the central and peripheral nervous system common: headache Uncommon: dizziness, sleep disorders, including insomnia and ” nightmarish “dream, asthenic syndrome, fatigue, paresthesia, hypoesthesia, disturbance of taste sensitivity, loss of or reduction in memory; rare: peripheral neuropathy.

On the part of the digestive tractoften: constipation, flatulence, dyspepsia, nausea, diarrhea uncommon: anorexia, vomiting, pancreatitis , hepatitis, abdominal pain, belching, rare: cholestatic jaundice (including obstructive); very rare:hepatic failure. On the part of the musculoskeletal system and connective tissue disorders common: myalgia, arthralgia, “swelling” of the joints, pain in the joints , back pain, muscle spasm; rare: pain in the muscles of the neck, muscle weakness; rare: myopathy, myositis, rhabdomyolysis, tendinopathy (sometimes complicated by rupture of a tendon); the frequency is unknown: . immune-mediated necrotizing anodrol myopathy From the senses uncommon: tinnitus , blurred vision, rare: blurred vision; very rare: hearing loss.

For the skin and subcutaneous tissue uncommon: urticaria, skin rash and itching, alopecia rare:angioneurotic edema, bullous eruption, polymorphic erythema (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome). On the part of metabolism often: hyperglycemia; rare:hypoglycaemia, weight gain. On the part of hematopoiesis rare: thrombocytopenia. The respiratory system is often: nasopharyngitis, sore throat, . nosebleeds Laboratory findings often: elevation of serum creatinine phosphokinase anodrol, increased activity of “liver” transaminases, rare: leucocyturia; the frequency is unknown: increasing the concentration of glycated hemoglobin. Other: rare: fatigue, violation of potency, secondary renal failure, fever body, chest pain, peripheral edema, very rare: gynecomastia, diabetes. . There are some reports about the development of atopic fasciitis (communication with atorvastatin is not certain), the frequency is not known: depression, interstitial lung disease (especially during prolonged therapy), sexual dysfunction.

 

Overdose

Specific anodrol antidote for the treatment of overdose is not.
In case of overdose should be symptomatic treatment.
Hemodialysis is ineffective (because the drug is significantly associated with plasma proteins).